RBC Life Sciences, Inc.
RBCL
$0.0001
$0.000.00%
| Weiss Ratings | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.62 | |||
| Price History | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1.00% | |||
| 30-Day Total Return | 1.00% | |||
| 60-Day Total Return | 1.00% | |||
| 90-Day Total Return | 1.00% | |||
| Year to Date Total Return | 1.00% | |||
| 1-Year Total Return | 1.00% | |||
| 2-Year Total Return | -99.22% | |||
| 3-Year Total Return | -79.80% | |||
| 5-Year Total Return | -99.98% | |||
| 52-Week High % Change | 0.00% | |||
| 52-Week Low % Change | 50.75% | |||
| Price | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.00 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Apr 18, 2024 | |||
| 52-Week High Price (Date) | Feb 21, 2025 | |||
| Valuation | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 4.26K | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -- | |||
| Earnings Per Share Growth | -- | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -- | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.00 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | -- | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 972 893 4000 | |||
| Address | 2301 Crown Court Irving, TX 75038 | |||
| Website | www.rbclifesciences.com | |||
| Country | United States | |||
| Year Founded | 1988 | |||
| Profitability | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -9.59% | |||
| Profit Margin | -2.32% | |||
| Management Effectiveness | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -10.04% | |||
| Return on Equity | -- | |||
| Income Statement | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 24.12M | |||
| Total Revenue (TTM) | 24.12M | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | 13.72M | |||
| EBITDA (TTM) | -1.79M | |||
| EBIT (TTM) | -2.32M | |||
| Net Income (TTM) | -559.50K | |||
| Net Income Avl. to Common (TTM) | -559.50K | |||
| Total Revenue Growth (Q YOY) | -28.06% | |||
| Earnings Growth (Q YOY) | 367.56% | |||
| EPS Diluted (TTM) | -0.25 | |||
| EPS Diluted Growth (Q YOY) | 349.17% | |||
| Balance Sheet | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 2.09M | |||
| Cash Per Share (Q) | $0.95 | |||
| Total Current Assets (Q) | 9.21M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 8.04M | |||
| Current Ratio (Q) | 2.160 | |||
| Book Value Per Share (Q) | -- | |||
| Total Assets (Q) | -- | |||
| Total Current Liabilities (Q) | 4.26M | |||
| Total Debt (Q) | -- | |||
| Total Liabilities (Q) | -- | |||
| Total Common Equity (Q) | 8.04M | |||
| Cash Flow | RBCL - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 4.48M | |||
| Cash from Financing (TTM) | -1.19M | |||
| Net Change in Cash (TTM) | 693.00K | |||
| Levered Free Cash Flow (TTM) | -2.59M | |||
| Cash from Operations (TTM) | -2.90M | |||
